Hoth Therapeutics, Inc. (HOTH)

Market Cap	5.08M
Revenue (ttm)	n/a
Net Income (ttm)	-11.37M
Shares Out	1.29M
EPS (ttm)	-0.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Oct 26, 2022

Volume	18,349
Open	3.88
Previous Close	3.91
Day's Range	3.76 - 4
52-Week Range	3.47 - 43.75
Beta	0.76
Analysts	Buy
Price Target	25.50 (+576.4%)
Earnings Date	Nov 16, 2022

About HOTH

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory b...

• Industry: Pharmaceuticals
• IPO Date: Feb 15, 2019
• Employees: 4
• Stock Exchange: NASDAQ
• Ticker Symbol: HOTH

Analyst Forecast

According to 8 analysts, the average rating for HOTH stock is "Buy." The 12-month stock price forecast is 25.5, which is an increase of 576.39% from the latest price.

Price Target

$25.5

(576.39% upside)

Analyst Consensus: Buy